Phaseline

Targets › HTR2A

HTR2A (5-hydroxytryptamine receptor 2A): drug programs, companies and trials

68 programs from 56 companies in 432 trials: 184 Phase 2, 105 Phase 1, 81 Phase 4, 62 Phase 3; Psychiatry, Neurology, Other; next expected readout Nov 2026.

G protein-coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). (UniProt, P28223)

Open in Phaseline: the race on HTR2A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Johns Hopkins UniversityTHC High Dose
Serotonin 2a (5-HT2a) receptor inverse agonist
CNR1, HTR2APhase 4Opioid Use; Cystic Fibrosis; Tobacco Dependence; Multiple Sclerosis …Nov 2026
Vanderbilt University Medical Center[18F]MH.MZ
Bacterial penicillin-binding protein inhibitor
HTR2A, UNKNOWN, BDKRB2, Ion channelsPhase 4Neurodegenerative Diseases; Osteoarthritis, Knee; Pain; Intradialytic Hypotension …Nov 2026
Brigham and Women's HospitalMIB 626 (NMN)
Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist
SLC5A2, SLC6A2, GLP1R, UNKNOWN, Tubulin, OPRM1, NR3C2, AGTR1, IL4R, SLC6A4, HTR2A, HTR2CPhase 4Prostate Cancer; Stable Coronary Disease; Allergic Contact Dermatitis; Hypertension …Nov 2026
Vanda Pharmaceuticalsiloperidone
Dopamine D2 receptor antagonist; Serotonin 2a (5-HT2a) receptor antagonist
DRD2, HTR2APhase 4Schizophrenia; HypertensionNov 2026
University of Pennsylvania2-[18F]-FA
Voltage-gated calcium channel modulator
CHRNA4, OPRK1, OPRD1, OPRM1, UL51, ADRA2A, ADRA2C, ADRA2B, Ion channels, CACNB4, CACNB2, CACNB1, CACNB3, TNF, SLC6A4, HTR2A, HTR2C, FKBP1A, CD86, CD80, PDE4A, PDE4D, PDE4B, PDE4C, PDE3A, CHRNB2, STNPhase 4Alcohol Use Disorder; Acute Kidney Injury; Insomnia; Giant Cell Arteritis …Nov 2026
The University of Texas Health Science Center, HoustonALA 10% gel
Muscle-type nicotinic acetylcholine receptor antagonist
HCRTR2, HCRTR1, CHRNA1, CHRNG, CHRNB1, CHRND, CHRNE, HTR2A, PTGS2, PTGS1Phase 4Anesthesia; Cleft Lip and Palate; Pancreatic Ductal Adenocarcinoma (PDAC); Stimulant Use Disorder …Dec 2026
University of California, San FranciscoIntravenous TXA
Interleukin-23 inhibitor
ADRB2, AGTR1, IL12B, IL23A, PDCD1, NR3C1, HTR2A, MAP2K1, MAP2K2, MS4A1, CHRM3, CHRM2, ADRB3, OPRM1, CYP19A1, CHRNB2, CHRNA4Phase 4Child Mortality; Relapsing Multiple Sclerosis; Menstrual Regulation; Secondhand Smoke …Dec 2026
University of CalgaryCBD 100 mg OD
Interleukin-23 inhibitor
CNR1, PLAT, IL12B, IL23A, ADRB2, HTR2A, NR3C1, TNF, PTGS2, PTGS1Phase 4Copd; Ehlers-Danlos Syndrome; Crohn Disease; Vasovagal Syncope …Dec 2026
John D. Dingell VA Medical CenterTrazodone
Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist
SLC6A4, HTR2A, HTR2CPhase 4Sleep ApneaDec 2026
Tongji Universitytrazodone
Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist
SLC6A4, HTR2A, HTR2CPhase 4Depressed Insomniac Co-morbid PatientsDec 2026
The University of Texas Health Science Center at San AntonioPimavanserin
Serotonin 2a (5-HT2a) receptor inverse agonist
HTR2APhase 4Parkinson's Disease PsychosisFeb 2027
The University of Texas Health Science Center at San AntonioQuetiapine
Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Dopamine D2 receptor antagonist
HTR2A, HTR2C, DRD2Phase 4Parkinson's Disease PsychosisFeb 2027
University of Texas Southwestern Medical Centerclozapine
Serotonin 2a (5-HT2a) receptor antagonist; Dopamine D2 receptor antagonist
HTR2A, DRD2Phase 4SchizophreniaApr 2027
VA Office of Research and Developmentpimavanserin
Serotonin 2a (5-HT2a) receptor inverse agonist
HTR2APhase 4Parkinson's Disease Psychosis; Post-traumatic Stress DisorderJul 2027
The Chaim Sheba Medical Centerrisperidone
Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Dopamine D2 receptor antagonist
HTR2A, HTR2C, DRD2Phase 4Velocardiofacial SyndromeAug 2027
Centre Hospitalier Universitaire, Amiensclozapine
Serotonin 2a (5-HT2a) receptor antagonist; Dopamine D2 receptor antagonist
HTR2A, DRD2Phase 4ClozapineSep 2027
Centre for Addiction and Mental HealthClozapine
Serotonin 2a (5-HT2a) receptor antagonist; Dopamine D2 receptor antagonist
HTR2A, DRD2Phase 4SchizophreniaSep 2027
Centre for Addiction and Mental HealthPaliperidone
Dopamine D2 receptor antagonist; Serotonin 2a (5-HT2a) receptor antagonist
DRD2, HTR2APhase 4Schizophrenia and Related DisordersSep 2027
Centre for Addiction and Mental HealthRisperidone
Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Dopamine D2 receptor antagonist
HTR2A, HTR2C, DRD2Phase 4Schizophrenia and Related DisordersSep 2027
New York State Psychiatric InstituteClozapine
Serotonin 2a (5-HT2a) receptor antagonist; Dopamine D2 receptor antagonist
HTR2A, DRD2Phase 4SchizophreniaJun 2028
Dr. Inge WinterClozapine
Serotonin 2a (5-HT2a) receptor antagonist; Dopamine D2 receptor antagonist
HTR2A, DRD2Phase 4Schizophrenia and Related DisordersJun 2028
Northwell Healtharipiprazole
Dopamine D2 receptor partial agonist; Serotonin 1a (5-HT1a) receptor partial agonist; Serotonin 2a (5-HT2a) receptor antagonist
DRD2, HTR1A, HTR2APhase 4Psychosis; Acute; Schizophenia DisorderDec 2029
Northwell Healthrisperidone
Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Dopamine D2 receptor antagonist
HTR2A, HTR2C, DRD2Phase 4Psychosis; Acute; Schizophenia DisorderDec 2029
Jimmi NielsenClozapine
Serotonin 2a (5-HT2a) receptor antagonist; Dopamine D2 receptor antagonist
HTR2A, DRD2Phase 4SchizophreniaDec 2029
Massachusetts General HospitalAripiprazole
Dopamine D2 receptor partial agonist; Serotonin 1a (5-HT1a) receptor partial agonist; Serotonin 2a (5-HT2a) receptor antagonist
DRD2, HTR1A, HTR2APhase 4Bipolar I DisorderFeb 2030
Massachusetts General HospitalLurasidone
Serotonin 2a (5-HT2a) receptor antagonist; Dopamine D2 receptor antagonist
HTR2A, DRD2Phase 4Bipolar I DisorderFeb 2030
Massachusetts General HospitalQuetiapine
Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Dopamine D2 receptor antagonist
HTR2A, HTR2C, DRD2Phase 4Bipolar I DisorderFeb 2030
VA Office of Research and DevelopmentTrazodone
Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist
SLC6A4, HTR2A, HTR2CPhase 4Sleep Disordered BreathingJun 2030
Northwell Healthclozapine
Serotonin 2a (5-HT2a) receptor antagonist; Dopamine D2 receptor antagonist
HTR2A, DRD2Phase 4Schizophenia DisorderJul 2030
Madigan Army Medical CenterCyclobenzaprine
Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist
HTR2A, HTR2CPhase 4Low Back Pain–
Chinese University of Hong KongTrazodone
Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist
SLC6A4, HTR2A, HTR2CPhase 4Mild Cognitive Impairment–
COMPASS PathwaysPsilocybin (COMP360)
Serotonin 2a (5-HT2a) receptor agonist
HTR2APhase 3Treatment Resistant Depression; Major Depressive Disorder; PTSD - Post Traumatic Stress Disorder; Depressive Disorder, Major …Dec 2026
Definium Therapeutics USDT120
5-HT2A receptor agonist
HTR2APhase 3Major Depressive Disorder; Generalized Anxiety DisorderFeb 2027
Intra-Cellular TherapiesLumateperone
Serotonin 2a (5-HT2a) receptor antagonist; Dopamine D2 receptor antagonist; Serotonin transporter inhibitor
HTR2A, DRD2, SLC6A4Phase 3Major Depressive Disorder; Irritability Associated With Autism Spectrum Disorder; Bipolar Depression; Schizophrenia …Apr 2027
Cybin IRLCYB003
Deuterated psilocin analog
HTR2APhase 3Major Depressive Disorder; Major Depressive Disorder (MDD); DepressionJun 2027
Shanghai Mental Health CenterAripiprazole
Dopamine D2 receptor partial agonist; Serotonin 1a (5-HT1a) receptor partial agonist; Serotonin 2a (5-HT2a) receptor antagonist
DRD2, HTR1A, HTR2APhase 3Treatment-resistant Schizophrenia; Obsessive-Compulsive DisorderJun 2027
OtsukaBrexpiprazole
Dopamine D2 receptor partial agonist; Serotonin 1a (5-HT1a) receptor partial agonist; Serotonin 2a (5-HT2a) receptor antagonist
DRD2, HTR1A, HTR2APhase 3Acute SchizophreniaSep 2027
ACADIA PharmaceuticalsACP-204
5-HT2A receptor antagonist/inverse agonist
HTR2APhase 3Lewy Body Dementia Psychosis; Alzheimer's Disease PsychosisJan 2028
Foundation for Advancing Veterans' Health ResearchQuetiapine Fumarate
Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Dopamine D2 receptor antagonist
HTR2A, HTR2C, DRD2Phase 3Mild Traumatic Brain InjuryJun 2028
Shanghai Mental Health CenterClozapine
Serotonin 2a (5-HT2a) receptor antagonist; Dopamine D2 receptor antagonist
HTR2A, DRD2Phase 3Treatment-resistant SchizophreniaDec 2030
University of North Carolina, Chapel HillCyclobenzaprine
Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist
HTR2A, HTR2CPhase 2Acute Stress ReactionNov 2026
Washington State UniversityMirtazapine
Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Adrenergic receptor alpha-2 antagonist
HTR2A, HTR2C, ADRA2A, ADRA2C, ADRA2BPhase 2Stimulant Use DisorderDec 2026
University of MichiganCyclobenzaprine
Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist
HTR2A, HTR2CPhase 2High Tone Pelvic Floor DysfunctionDec 2026
University of Triestemirtazapine
Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Adrenergic receptor alpha-2 antagonist
HTR2A, HTR2C, ADRA2A, ADRA2C, ADRA2BPhase 2RETT Syndrome With Proven MECP2 MutationDec 2026
Ohio State UniversityPimavanserin
Serotonin 2a (5-HT2a) receptor inverse agonist
HTR2APhase 2Intermittent Explosive DisorderJan 2027
M.D. Anderson Cancer CenterChlorpromazine
Serotonin 2a (5-HT2a) receptor antagonist; D2-like dopamine receptor antagonist
HTR2A, DRD2, DRD3, DRD4Phase 2DeliriumFeb 2027
M.D. Anderson Cancer CenterHaloperidol
Serotonin 2a (5-HT2a) receptor antagonist; D2-like dopamine receptor inverse agonist
HTR2A, DRD2, DRD3, DRD4Phase 2Delirium; Advanced Malignant Neoplasm; Advanced CancersFeb 2027
Boryung PharmaceuticalOlanzapine
Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; D2-like dopamine receptor antagonist
HTR2A, HTR2C, DRD2, DRD3, DRD4Phase 2Schizophrenia; Schizophrenia and Related Disorders; Chemotherapy Induced Nausea and Vomiting; Oncology Patients Receiving Chemotherapy …May 2027
Centre hospitalier de l'Université de Montréal (CHUM)Trazodone
Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist
SLC6A4, HTR2A, HTR2CPhase 2Insomnia ChronicJul 2027
Hospices Civils de Lyon[18F]-altanserin
5-HT2A receptor ligand for PET imaging
HTR2APhase 2Tourette DisorderSep 2027
Memorial Sloan Kettering Cancer CenterFlibanserin
Serotonin 1A receptor agonist, serotonin 2A receptor antagonist, and serotonin reuptake in
HTR1A, HTR2A, SLC6A4Phase 2Breast CancerOct 2027
New York State Psychiatric InstitutePimavanserin Tartrate
Serotonin 2a (5-HT2a) receptor inverse agonist
HTR2APhase 2Autism Spectrum DisorderOct 2027
M.D. Anderson Cancer CenterMirtazapine
Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Adrenergic receptor alpha-2 antagonist
HTR2A, HTR2C, ADRA2A, ADRA2C, ADRA2BPhase 2Advanced CancerDec 2027
NeuroRxNRX-101
D-cycloserine (NMDA co-agonist/glycine site modulator) + Lurasidone (5-HT and dopamine ant
GLRA1, HTR2APhase 2Treatment Resistant DepressionDec 2027
Tonix PharmaceuticalsCyclobenzaprine Hydrochloride (TNX-102)
Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist
HTR2A, HTR2CPhase 2Major Depressive Episode (MDE); PharmakokineticFeb 2028
Lone BaandrupQuetiapine
Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Dopamine D2 receptor antagonist
HTR2A, HTR2C, DRD2Phase 2Psychiatric DisordersFeb 2029
Icahn School of Medicine at Mount SinaiPimavanserin
Serotonin 2a (5-HT2a) receptor inverse agonist
HTR2APhase 2Major Depressive DisorderMar 2029
Centre Hospitalier St AnneTrazodone
Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist
SLC6A4, HTR2A, HTR2CPhase 2Depression - Major Depressive DisorderDec 2029
University of California, IrvineMirtazapine
Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Adrenergic receptor alpha-2 antagonist
HTR2A, HTR2C, ADRA2A, ADRA2C, ADRA2BPhase 2Glioma of BrainDec 2030
TRYP TherapeuticsTRP-8802
Psilocybin; serotonin 5-HT2A receptor agonist
HTR2APhase 2Irritable Bowel Syndrome–
Md. Moktadirul Hoque ShuvoTrifluoperazine
Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; D2-like dopamine receptor antagonist
HTR2A, HTR2C, DRD2, DRD3, DRD4Phase 2Functional Dyspepsia–
Yale UniversityDimethyltryptamine (DMT)
Serotonin 5-HT receptor agonist; endogenous psychedelic compound
HTR1A, HTR1B, HTR1D, HTR2APhase 1Major Depressive Disorder; Alcohol Use Disorder (AUD)Dec 2026
University of ArizonaZiprasidone
Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Dopamine D2 receptor antagonist
HTR2A, HTR2C, DRD2Phase 1SchizophreniaFeb 2027
Sichuan Kelun PharmaceuticalBrexpiprazole
Dopamine D2 receptor partial agonist; Serotonin 1a (5-HT1a) receptor partial agonist; Serotonin 2a (5-HT2a) receptor antagonist
DRD2, HTR1A, HTR2APhase 1Schizophrenia Disorders; Major Depressive Disorder; Bipolar Depression; Alcohol Use Disorder–
Capital Medical UniversityChlorpromazine
Serotonin 2a (5-HT2a) receptor antagonist; D2-like dopamine receptor antagonist
HTR2A, DRD2, DRD3, DRD4Phase 1Acute Ischemic Stroke–
University Hospital, Basel, SwitzerlandKetanserin
Serotonin 5-HT2A receptor antagonist
HTR2APhase 1Healthy–
Scottsdale Research InstituteOrganic Whole Psilocybin-Containing Mushrooms
Psilocybin (5-HT2A serotonin receptor agonist)
HTR2APhase 1PTSD–
Verinder SharmaQuetiapine
Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Dopamine D2 receptor antagonist
HTR2A, HTR2C, DRD2Phase 1Postpartum Depression–

Conditions

Major Depressive Disorder (15) Schizophrenia (11) Alcohol Use Disorder (10) Treatment Resistant Depression (8) Opioid Use Disorder (7) Healthy (6) Multiple Sclerosis (6) PTSD (5) Alcohol Use Disorder (AUD) (5) Depression (4) Advanced Cancer (4) Post Traumatic Stress Disorder (4)

Modalities

small molecule (64), protein or peptide (3)

Companies

M.D. Anderson Cancer Center (3) Centre for Addiction and Mental Health (3) Northwell Health (3) Massachusetts General Hospital (3) VA Office of Research and Development (2) Shanghai Mental Health Center (2) New York State Psychiatric Institute (2) The University of Texas Health Science Center at San Antonio (2) Cybin IRL (1) Scottsdale Research Institute (1) COMPASS Pathways (1) ACADIA Pharmaceuticals (1) Vanda Pharmaceuticals (1) Intra-Cellular Therapies (1) Definium Therapeutics US (1) The Chaim Sheba Medical Center (1) Memorial Sloan Kettering Cancer Center (1) Verinder Sharma (1) Sichuan Kelun Pharmaceutical (1) Johns Hopkins University (1)

Related targets

DRD2 (31) HTR2C (27) SLC6A4 (10) HTR1A (7) ADRA2A (5) ADRA2C (5) ADRA2B (5) DRD3 (5) DRD4 (5) OPRM1 (3) CNR1 (2) ADRB2 (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.